Lead Product(s) : Galcanezumab
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Agreement
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Details : Under the agreement, Organon becomes the sole distributor and promoter of Emgality (galcanezumab), a humanized monoclonal antibody calcitonin gene-related peptide (CGRP) antagonist, and RAYVOW™ (lasmiditan), a first-in-class serotonin 5-HT1F receptor a...
Product Name : Emgality
Product Type : Antibody
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Galcanezumab
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Agreement